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ABSTRACT: The present study evaluates the effects of two commercial phytotherapic formulations
containing Glycine max (L.) Merr. (Soy) (Phytotherapic A and Phytotherapic B) on Wistar rat fertility.
Doses were based on the manufacturer’s recommendation and increased in a logarithmic scale. The
animals were divided into six experimental groups and a control group, which received distillated
water. Three groups were treated with Phytotherapic A and three groups were treated with
Phytotherapic B. The doses were: 4.3mg.kg-1.day-1, 21.5 mg.kg -1.day-1 and 43 mg.kg -1.day-1,
respectively, for GPA1, GPA2, GPA3, and GPB1, GPB2, GPB3. The males were treated during
ninety-one days, before and during the mating.  Female Wistar rats were treated before and during
the mating, pregnancy and lactation. The total number of spermatozoa, their daily production sperm
morphology, histopathology and weight of sexual organs were evaluated. The results showed the
interference of the phytotherapic formulations A and B in the total number of spermatozoa and in
the sperm morphology in a dose-dependent manner.
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EFECTOS DE DOS FORMULACIONES FITOTERAPÉUTICAS QUE CONTIENEN Glycine
max (L.) MERR SOBRE LA FERTILIDAD DE RATAS MACHOS
RESUMEN: El presente estudio evalúa los efectos de dos formulaciones comerciales que contienen
fitoterapéuticos Glycine max (L.) Merr. (Soja) (fitoterapéutico A y fitoterapéutico B) sobre la fertilidad
de ratas Wistar. Las dosis se basaron en las recomendaciones del fabricante y el aumento en una escala
logarítmica. Los animales se dividieron en seis grupos experimentales y un grupo control, que recibió
agua destilada. Tres grupos fueron tratados con un fitoterapéutico y tres grupos fueron tratados con
fitoterapéutico B. Las dosis fueron: 4 .3mg.kg -1.day-1, 21,5 mg.kg -1.day-1 y 43 mg.kg -1.day-1,
respectivamente, para GPA1, GPA2, GPA3 y GPB1, GPB2, GPB3. Los machos fueron tratados
durante noventa y un días, antes y durante el apareamiento. Las Hembras Wistar fueron tratadas
antes y durante el apareamiento, el embarazo y la lactancia. Número total de espermatozoides, la
producción diaria de espermatozoides, la morfología del esperma, la histopatología y el peso de los
órganos sexuales fueron evaluados. Los resultados mostraron la interferencia de las formulaciones
fitoterapéuticos A y B en e l número total de e spermatozoides y en la  morfología de los
espermatozoides de una manera dosis-dependiente.
(Palabras clave: soja; Glycine max; fitoterapéuticos; ratas machos; fertilidad; toxicidad)
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INTRODUCTION
Soybean is a leguminous species of the Fabaceae
family, rich in phytochemical compounds, especially
isoflavones. Products derived from the soybean (such
as flour, milk, or tofu) contain significant concentrations
of isoflavones.
Isoflavones are members of the polyphenol group
and their chemical structure is closely related to human
estrogen. They are capable of inducing marked hormonal
effects and are designated phytoestrogens (1).
There is extensive literature covering the use of
soybean for prevention and treatment of several
diseases. The therapeutic indications include: milk
substitution for allergic children, management of pre-
and post-menopausal symptoms, prevention of
osteoporosis, prevention and treatment of cancer,
prevention of cardiovascular diseases, and as an
adjuvant to the handling of diabetes.  However, many
contradictory studies report toxic effects of isoflavones
on fertility.
Moreover, there is substantial bibliography regarding
potential adverse outcomes from the ingestion of
soybean and its isoflavones. Among others, interference
in the immunological system, changes in thyroid
function, reduction of vitamins and minerals absorption,
impairment of the myelinization process, triggering of
cancer and damage to DNA chain have been recorded
(2, 3, 4, 5).
The best documented effects are related to the
activity on reproduction. With this regard, soybean and
its isoflavones are classified as endocrinal disrupters
(6, 7, 8). In vitro studies have shown that genistein
induces apoptosis of testicular cell lines, and inhibits
their growth and proliferation. Also, it may interfere with
percentage of sperm motility and modulate sperm
capacitation, acrossome reactions, and fertilizing ability.
Histopathologic findings in males included ductal
alveolar hyperplasia and hypertrophy in the mammary
glands; aberrant  or delayed spermatozoa and
decreased sperm in the epididymis (9, 10, 11, 12).
The consumption of pharmaceutical products based
on soybean and claimed as natural substances has
grown exponentially, representing a real danger for public
health since many of the active principles of soybean
have not been well evaluated. Therefore, studies about
the toxici ty  of such phytotherapics,  bes ides
assessment of their safety and efficacy on rat fertility
have become a matter of highest necessity.
The present study has evaluated the effects of two
phytotherapic preparations on the fertility and
reproductive performance of male Wistar rats (13). It is
part of a larger appraisal about the reproductive toxicity
of soybean-based phytotherapic substances that was
recommended by the Federal Drug Administration (FDA)
and the Organization for Economic Cooperation and
Development (OECD).
METHODS
Phytotherapic formulations
The phytotherapic formulations used in the
experiments were acquired in local pharmaceutical
establishments, containing the same batch number and
date of manufacture and were within the validity period
in all cases. The corporate name for Phytotherapic A
was Ache Laboratórios Farmacêuticos S/A, and for
Phytotherapic B was Herbarium Laboratório Botânico
Ltda. The declared composition in the package leaflet
of Phytotherapic A was dry extract of Glycine max (L.)
Merr. 40% in 150mg capsule and of Phytotherapic B
was dry extract of Glycine max (L.) Merr 40% in the
75mg capsule. The experimental doses were obtained
based on the manufacturer’s recommendations as
follows: G1 – the therapeutic dose (4.3mg.kg-1), G2 –
five times therapeutic dose (21.5 mg.kg-1), G3 – ten
times therapeutic dose (43mg.kg-1). The phytotherapic
formulations were prepared through the dilution of the
contents of the capsules, using distilled water as a
vehicle, stored in amber vial and kept under refrigeration.
Quantification of isoflavones
Confirmation of the isoflavones levels per capsule of
the Phythoterapic was performed by high performance
liquid chromatography (HPLC).
HP1100 liquid chromatograph (Agilent, CA, USA)
consisting in quaternary pump, degasser, autosampler,
diode array detector (DAD) were used under
chromatographic conditions described by César et al.
(14). Conjugates malonyl-glucosides and total
isoflavones as aglycones were calculated based on their
molecular weight. The content of isoflavones found in
the sample was: daidzin: 8.93%, genistin: 3.89%,
Daidzein: 25.75%, Genistein: 16.61% (GPA) and,
daidzin: 8.04%, genistin: 3.05%, Daidzein: 25.6%,
Genistein: 15.65% (GPB). The results ensured the
isoflavones levels produced by the laboratories.
Animals
The 24 males and 72 females albino Wistar rats from
the Center of the Reproduction and Experimentation of
Laboratory Animals  of the Universidade Federal do Rio
Grande do Sul (UFRGS) were kept under a day/night
cycle (lights on 9:00 am to 9:00 pm), room temperature
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21ºC ± 1, and 50% ± 5 relative humidity. The animals
received a standard pellet diet (Nuvital CR 1®, Paraná,
Brazil) and tap water ad libitum throughout the
experiment. The rats were adapted to these conditions
in their own animal quarters for 2 weeks before starting
the experiment. Breeding, housing, and experimental
procedures followed guidelines published in the NIH
Guide for Care and Use of Laboratory Animals and were
in accordance with current Brazilian regulations including
approval by the Research Ethics Committee of UFRGS.
Mating procedure
Males were housed individually in a cage with wood
shavings as bedding. Three virgin females were placed
into a male cage for 2 hours each (7:00 am to 9:00
am) and vaginal smears were collected (9:00 am) and
examined for the presence of sperm. The mating
procedure was repeated from Monday to Friday for 3
weeks.
Treatment schedule
The animals were divided into 7 groups composed
of 8 males and 24 females each. A control group
received only distillated water vehicle (CG). The other
six groups received the therapeut ic doses of
Phytotherapic A and Phytotherapic B, five times the
therapeutic dose, and ten times the therapeutic dose
(4.3mg.kg-1.day-1, 21.5 mg.kg-1.day-1  and 43 mg.kg-
1.day), respectively  GPA1, GPA2, GPA3, GPB1, GPB2
and GPB3. All animals in the experimental groups were
dosed once dai ly  by gavage, the volume of
administration was equivalent to 10ml.kg-1. Male rats
were dosed for 91 days (70 days before mating and 21
during mating). Females were dosed before mating (14
days) and during mating (21 days), pregnancy (21 days),
and lactation periods (21 days).
Animal evaluation
All males and females were assessed daily for weight
development, mortality, and toxicity signs. Pregnant
females were monitored for weight gain, signs of
abortion, dystocia, and prolonged duration of pregnancy.
Fertility evaluation
On the 21st day of pregnancy, half of the females
was anaesthetized with tiletamin/ zolazepan 50% and
euthanatized by decapitation. After the collection of
uterus and ovaries, resorptions as well as living and
dead fetuses were counted and the number of
implantation sites was determined (data not shown).
Male examination procedure
All male rats were euthanized by decapitation after
tiletamin/zolazepan 50% anesthesia at the end of the
mating period and necropsied. Organs were inspected
macroscopically, weighed and fixed in 10% neutral
buffered formalin for routine processing and light-
microscopic evaluation of sections stained with
hematoxylin-eosin. One animal/group had its testis
removed immediately after being euthanized. The
testis was fixed in Bouin’s solution, embedded in
paraffin and stained with hematoxylin-eosin for
histological examination.
Spermatid and sperm numbers
Testes and epididymis were removed after the
animals were euthanazed. The testis was rinsed and
homogenized in 10 ml 0.9 % NaCl containing 0.5 %
triton X-100 at medium speed in a Fisaton 720®
tissuemizer for 1 min, after removal of the albuginea
tunic. The number of homogenization-resistant
spermat ids was counted in a hematocytomer
(Neubauer). The cauda epididymis was also rinsed,
homogenized, and spermatozoa counted in the
hematocytomer.
The number of sperm and daily sperm production
was determined as follows: Number of sperm (S) = Csx FC x V; and daily sperm production – Cd x FC x V: 6,
1; S = total number per animal. FC = chamber factor
(1.250). V = dilution (106). Cs = number of sperms
counted. Cd = number of homogenization-resistant
spermatids counted.
Sperm morphology assessment
To assess the percentage of morphologically
abnormal sperm (defects in head, body or tail piece),
the ductus deferens was rinsed with 1M 0.9 % NaCl
and a sperm suspension was subsequently obtained.
An aliquot of sperm suspension was stained with 2 %
eosin to assess the percentage of morphologically
abnormal sperm. Two hundred sperm/animal were
analyzed microscopically at a magnification of 400
t imes and were recorded as being e i ther
morphologically normal or abnormal. The abnormal
sperm was classified according to defects in head or
in cauda. The head alteration categories were
outstanding, malformation and missing. The cauda
alteration categories were outstanding, broken and
cauda with intense folding.
Statistical analysis
Data were analyzed by one-way analysis of variance.
Bonferroni test was used to identify differences between
groups in the control group. Proportions were analyzed
by the Chi-square test. Statistical evaluation was
performed using Excel and SPSS for Windows
programs, and P< 0.05 was considered significant.
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RESULTS
Body weight gain and toxicity
The administration of phytotherapics for 91 days
prior to mating and during the mating period did not
induce death or toxicity. There were no statistically
significant differences in body weight gain among the
groups at the three doses of Phytotherapics A and B
(data not shown).
Organ weights
Treatment with Phytotherapic A resulted in
statistically significant differences in absolute and/or
relative weights of livers, epididymides, and seminal
vesicle. Testis, prostate, kidneys, livers, spleens and
hearts of the animals examined did not show statistically
significant differences. The treatment with Phytotherapic
B showed statistically significant differences in absolute
weights of epididymides. Testes, accessory glands
(prostate and seminal vesicle), kidneys, livers, spleens
and hearts of the animals examined did not show
statistically significant differences.
Histology
Light microscopic evaluation did not reveal
morphological alterations in the examined organs of
male rats treated with Phytotherapic A and B at the
three doses.
Sperm number and daily sperm production
The number of sperm in the caudal epididymides in
male rats treated with Phytotherapic A and B resulted
in statistically significant differences at a higher dose
(43 mg.kg-1.day-1) (Fig 1). Daily sperm productions also
resulted in statistically significant differences, but at a
lower dose (4.3 mg.kg-1.day-1) (Fig 2).
FIGURE 1. Number of sperm/group in male rats treated with Phytotherapic A (Graph A) and Phytotherapic B (Graph B) at
three doses and the control group for 91 days (prior and during mating). Data were analyzed by ANOVA and Bonferroni test.
Values are means/group. * Significantly different (P<0. 05) from the control group./  Número de espermatozoides/grupo de
ratas macho tratadas con Fitoterapéutico A (grafico A) y Fitoterapéutico B (grafico B) en tres dosis y el grupo control
de 91 días (antes y durante el apareamiento). Los datos analizados por ANOVA y test de Bonferroni. Los valores son
medias / grupo. * Significativamente diferente (p <0. 05) del grupo control.
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Sperm Morphology
The number and percentage of morphologically
abnormal sperm in males treated with Phytotherapic A
and B resulted in statistically significant differences
from the control group at the three doses (Fig 3).
DISCUSSION
The phytoestrogens of the soy are molecules of plant
origin with numerous biological properties, but the best
known is that they behave like weak estrogens. Evidence
from animal studies suggests that the ingestion of very
high amounts of phytoestrogens may affect fertility.
Sheep exposed to great amounts of clover forage
presents infertility, ewes fed with estrogenic forage may
suffer impaired ovarian function, often accompanied by
reduced conception rates and increased embryonic loss.
In cattle, phytoestrogens cause irregular estrus,
nymphomania, anestrus, and ovarian cysts (15).
In males, estrogenic compounds can be toxic to
testicular tissue in rodents and humans (16). Fertility
of the human male is particularly susceptible to agents
that reduce the number or quality of sperm produced.
Compared to many other species, human males
produce fewer sperm in relation to the number of sperm
required for fertility (17, 18). As a result, many men are
subfertile or infertile (18). If the number of normal sperm
per ejaculation is sufficiently low, fertilization is unlikely
and an infertile condition exists (19). However,
isoflavones are able to exert non-genomic actions
potentially injurious to male fertility (20). Rodents can
also be sensitive to the effects of isoflavones, as
FIGURE 2. Daily sperm production in male rats treated for 91 days with Phytotherapic A(Graph A) and Phytotherapic B
(Graph B) at three doses and the control group. Data were analyzed by ANOVA and Bonferroni test. Values are means/group.
* Significantly different (P<0. 05) from the control group./ La producción de espermatozoides al día en las ratas macho
tratadas durante 91 días con Fitoterapéutico A (grafico A) y Fitoterapéutico B (grafico B) en tres dosis y el grupo
control. Los datos analizados por ANOVA y test de Bonferroni. Los valores son medias/grupo. * Significativamente
diferente (p <0. 05) del grupo control.
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genistein can inhibit the growth and proliferation of
testicular cells. In mice, it was shown that genistein
can deregulate the spermatogenesis and reduce the
number of sperm in the epididymis (9).
Various studies show that treatment of male rats
with estrogenic chemicals reduces testicular and
epididymal sperm concentration and Sertoli cell
number, alters testicular gene expression, and causes
rete tubule distension and reduced epithelial height in
the efferent ducts (21, 22, 23, 24).
Global declines in semen quality were suggested
to be assoc iated wi th enhanced exposure to
environmental chemicals that act as endocrine
disrupters as a result of our increased use of pesticides,
plastics, phytoestrogens and other anthropogenic
materials (25). Considerable toxicology data based upon
laboratory and wildlife animal studies suggest that
exposure to certain endocrine disrupters is associated
with reproductive toxicity, including abnormalities of the
male reproductive tract (cryptorchidism, hypospadias),
reduced semen quality, and impaired fertility in the adult
(26, 27, 28, 29, 30).
In humans, a study assessed 99 male partners of
subfertile couples as the intake of isoflavones in the
diet. As a result it was observed that there was an
inverse association between soy food intake and that
sperm concentration significant remained after
accounting for age, abstinence time, body mass index,
caffeine and alcohol intake and smoking. In conclusions,
these data suggest that a higher intake of soy foods
and soy isoflavones is associated with a lower sperm
concentration (31).
FIGURE 3. Number of morphologically abnormal sperm in male rats treated orally during 91 days with Phytotherapic A
(Graph A) and Phytotherapic B (Graph B)  at three doses and the control group. Data were analyzed by the Chi-square test.
*Significantly different (P<0.01) from the control group./ Número de espermatozoides morfológicamente anormales en las
ratas macho tratadas por vía oral durante 91 días con fitoterapéutico A (grafico A) y Fitoterapéutico B (Grafico B) en
tres dosis y el grupo control. Los datos analizados por la prueba de Chi-cuadrado. *Significativamente diferente
(p<0,01) del grupo control.
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Data from this study suggest that male rats exposed
to the daily oral administration of the two phytotherapic
preparations (Phytotherapic A and Phytotherapic B) for
91 days prior to and during the mating period did not
have any systemic toxicity. However, both were able to
reduce the epididymis weight, without promoting
histological alterations. Both phytotherapic formulations
decreased the total number of sperm stored in the
epididymis at the highest dose and increased the sperm
morphology changes in a dose-dependent manner.
The epididymis, a steroid-dependent organ, is
responsible for the post-testicular maturation and
storage of sperm. Because of the composition of the
sperm plasma membrane and its lack of cytoplasm,
sperm in the epididymis is susceptible to damage from
reactive oxygen species (32).
An increase in abnormal sperm morphology has
been considered as evidence that the agent has gained
access to germ cells (33, 34). Sperm morphology
profiles are relatively stable and characteristic in a
normal individual (and a strain within a species) over
time.
The litters of males exposed to Phytotherapic A and
Phytotherapic B and the controls negative and positive
were also evaluated for overall and sexual development,
and behavior on the open field. No change related to
the administration of isoflavones was found (35).
To identify possible effects of isoflavones on male
fertility, reproductive parameters were evaluated in
Wistar-Unilever rats receiving dietary exposure to PTI
G-2535, a characterized mixture of soy-derived
isoflavones containing 45% genistein, 23% daidzein,
and 4% glycitein. Rats received chronic dietary
exposure to the soy isoflavone mixture (200 or 2000
mg/kg diet) for a minimum of 12 months. Dietary
exposure to isoflavones induced no gross toxicity or
alterations in body weight gain. Histopathologic
evaluations demonstrated that testicular morphology
was similar in all study groups (36).
In conclusion, this study suggests that both
Phytotherapic formulat ions have acted on the
epididymis of the animals, causing decrease dose-
dependent in the weight of the organ without causing a
decrease in animal weight, reducing the number of
sperm at the highest dose used and increasing the
percentage of spermatozoa with morphological
alterations however, the results reinforce the data
observed in related literature, concerning the effects of
soy isoflavones on male fertility.
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